Guggenheim Reiterates Buy Rating on Natera, Inc. (NTRA)
Guggenheim maintained its buy rating on Natera with a $290 target, a 8.60% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Natera, Inc. (NTRA) with a $290 price target on June 29, 2026.
- Guggenheim's $290 price target implies 8.60% upside from Natera, Inc.'s ($NTRA) current $267.05 share price.
- Shares of NasdaqGS:NTRA traded near $266.22 on Monday with a market cap of about $37.5 billion.
- Insiders at Natera sold shares under planned sales, while analysts show strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating on Natera, Inc. (NasdaqGS: NTRA) on June 29, 2026, with a price target of $290. This reflects continued confidence in the diagnostics company's future prospects. Shares of Natera traded near $266.22 on Monday.
Other Institutional Activity in Natera, Inc.
Several institutional investors have been active in Natera recently. JPMorgan Chase & Co. increased its stake by 532,333 shares, bringing its total to 13,386,667 shares valued at approximately $2.5 billion, marking a 4.1% increase. Price T Rowe Associates Inc. boosted its holdings by 1,312,887 shares, ending with 12,184,876 shares worth about $2.4 billion, a 12.1% increase. Meanwhile, BlackRock, Inc. trimmed its position by 182,103 shares, resulting in 10,677,338 shares valued at $2.1 billion, a decrease of 1.7%. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions, with 6,008,496 and 5,644,695 shares valued at $1.2 billion and $1.1 billion, respectively.
Natera, Inc. Stock Down 18.1%
Shares of Natera, Inc. (NasdaqGS: NTRA) traded near $266.22 on Monday. The company has a market capitalization of approximately $37.5 billion. Despite not being profitable, Natera has a forward P/E ratio of -1256.89 and a beta of 1.544, indicating higher volatility compared to the market. The stock's 52-week range is between $131.81 and $271.47, with a 50-day moving average of $212.40 and a 200-day moving average of $208.58. The company's current ratio is 2.959, and its quick ratio is 2.697, suggesting good short-term liquidity, while the debt-to-equity ratio stands at 13.533.
$NTRA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Natera reported revenue of $2.5 billion with a growth rate of 38.8%. However, the company is not yet profitable, with a net margin of -9.05% and a return on equity of -15.02%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Natera, Inc.
Recent insider activity at Natera shows planned sales by several executives. On June 24, 2026, Herm Rosenman sold 16,530 shares at an average price of $250. Daniel Rabinowitz, the Chief Legal Officer, sold 33,600 shares at $251.65 per share. Earlier, on June 17, Jonathan Sheena sold 1,500 shares at $219.88, and Rowan Chapman sold 2,964 shares at $216.78 on June 16. These transactions were part of pre-arranged trading plans.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Natera, setting a price target of $290. Bernstein reiterated a buy rating with a target of $310 on June 26. BTIG maintained its buy rating with targets of $275 and $270 on June 24 and June 23, respectively. Barclays also maintained a buy rating with a $260 target on June 24. Overall, the consensus rating for Natera is a strong buy, with a mean price target of $262.67 based on 21 analyst opinions.
About Natera, Inc.
Natera, Inc. is a healthcare company based in Austin, Texas. It specializes in developing and selling molecular testing services globally. The company offers a range of tests, including Signatera for cancer monitoring, Latitude for colorectal cancer, and Panorama for prenatal screening. Natera, led by CEO Steven Leonard Chapman, employs over 6,000 people and partners with labs and medical centers worldwide. Founded in 2003, Natera continues to innovate in the diagnostics and research industry.
Bottom Line
Guggenheim's reiteration of a buy rating for Natera underscores confidence in the company's growth potential in the diagnostics sector. While the stock is not yet profitable, its innovative products and strong market presence attract significant institutional interest. Investors should note that analyst ratings are based on past data and may not reflect current conditions.
Get Natera, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NTRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.